Keenan P A, Jacobson M W, Soleymani R M, Mayes M D, Stress M E, Yaldoo D T
Department of Psychiatry, Wayne State University School of Medicine, Detroit, Michigan, USA.
Neurology. 1996 Dec;47(6):1396-402. doi: 10.1212/wnl.47.6.1396.
There have been no systematic investigations of the effects of glucocorticoid treatment on memory in a clinical population despite experimental and clinical evidence that such treatment could cause memory disturbance. We conducted both cross-sectional and longitudinal studies. In Study 1, we administered tests of both hippocampal-dependent explicit memory and hippocampal-independent implicit memory to twenty-five prednisone-treated patients with systemic disease without CNS involvement and 25 matched clinical controls. All treated patients were taking doses of 5 to 40 mg of prednisone daily for at least 1 year. The glucocorticoid-treated group performed worse than the controls on tests of explicit memory, but the groups did not differ on the implicit memory task. Multiple regression analyses suggested that elderly patients are more susceptible to memory impairment with less protracted treatment. The results of Study 2, a prospective, longitudinal study of the effects of prednisone on memory across 3 months of therapy, suggest that even acute treatment can adversely affect memory. The observed alteration in memory was not secondary to inattention, affective disturbance, generalized global cognitive decline, or severity of disease. Results reported here, combined with previous clinical and experimental reports, indicate that the risk of memory impairment should be carefully considered before initiating treatment with glucocorticoids. Conversely, use of glucocorticoids should be considered in the differential diagnosis of memory loss. Finally, the potential benefit of anti-inflammatory treatment in Alzheimer's disease might be counterbalanced by possible iatrogenic memory impairment, at least when synthetic glucocorticoids are considered.
尽管有实验和临床证据表明糖皮质激素治疗可能导致记忆障碍,但尚未对临床人群中糖皮质激素治疗对记忆的影响进行系统研究。我们进行了横断面研究和纵向研究。在研究1中,我们对25名接受泼尼松治疗的无中枢神经系统受累的全身性疾病患者和25名匹配的临床对照者进行了海马依赖性外显记忆和海马非依赖性内隐记忆测试。所有接受治疗的患者每天服用5至40毫克泼尼松,至少服用1年。糖皮质激素治疗组在外显记忆测试中的表现比对照组差,但在隐记忆任务上两组没有差异。多元回归分析表明,老年患者在治疗时间较短时更容易出现记忆障碍。研究2是一项关于泼尼松在3个月治疗期间对记忆影响的前瞻性纵向研究,其结果表明,即使是急性治疗也会对记忆产生不利影响。观察到的记忆改变并非继发于注意力不集中、情感障碍、全面的认知衰退或疾病严重程度。此处报告的结果,结合之前的临床和实验报告,表明在开始糖皮质激素治疗前应仔细考虑记忆障碍的风险。相反,在记忆丧失的鉴别诊断中应考虑使用糖皮质激素。最后,至少在考虑合成糖皮质激素时,阿尔茨海默病抗炎治疗的潜在益处可能会被可能的医源性记忆障碍所抵消。